Antonio Ojeda

Antonio Ojeda

Auto-generated profile, based on publicly available information

Antonio Ojeda

Servicio de Anestesiología, Hospital Clínic de Barcelona, Universitat de Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in European journal of pain
Verified
Journal Article
Open access
PDF file
AOAntonio Ojeda
Antonio Ojeda
ACAndrea Calvo
Andrea Calvo
TCTomas Cuñat
Tomas Cuñat
RMRicard Mellado‐Artigas
Ricard Mellado‐Artigas
OCOscar Comino‐Trinidad
Oscar Comino‐Trinidad
CDChristian Dürsteler
Christian Dürsteler
Background: Pain is a clinical feature of COVID‐19, however, data about persistent pain after hospital discharge, especially among ICU survivors is scarce. The aim of this study was to explore the incidence and characteristics of new‐onset pain and its impact on Health‐Related Quality of Life (HRQoL), and to quantify the presence of mood disorders in critically ill COVID‐19 survivors.Methods: This is a preliminary report of PAIN‐COVID trial (NCT04394169) presenting a descriptive analysis in critically ill COVID‐19 survivors, following in person interview 1 month after hospital discharge. Pain was assessed using the Brief Pain Inventory, the Douleur Neuropathique 4 questionnaire and the Pain Catastrophizing Scale. HRQoL was evaluated with the EQ 5D/5L, and mood disorders with the Hospital Anxiety and Depression Scale (HADS).Results: From 27 May to 19 July 2020, 203 patients were consecutively screened for eligibility, and 65 were included in this analysis. Of these, 50.8% patients reported new‐onset pain; 38.5% clinically significant pain (numerical rating score ≥3 for average pain intensity); 16.9% neuropathic pain; 4.6% pain catastrophizing thoughts, 44.6% pain in ≥2 body sites and 7.7% widespread pain. Patients with new‐onset pain had a worse EQ‐VAS and EQ index value (p < 0.001). Pain intensity was negatively correlated to both the former (Spearman ρ: −0.546, p < 0.001) and the latter (Spearman ρ: −0.387, p = 0.001). HADS anxiety and depression values equal or above eight were obtained in 10.8% and 7.7% of patients, respectively.Conclusion: New‐onset pain in critically ill COVID‐19 survivors is frequent, and it is associated with a lower HRQoL.Trial registration No.: NCT04394169. Registered 19 May 2020. https://clinicaltrials.gov/ct2/show/NCT04394169.Significance: A substantial proportion of severe COVID‐19 survivors may develop clinically significant persistent pain, post‐intensive care syndrome and chronic ICU‐related pain. Given the number of infections worldwide and the unprecedented size of the population of critical illness survivors, providing information about the incidence of new‐onset pain, its characteristics, and its influence on the patients’ quality of life might help establish and improve pain management strategies.

7 February 2022 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
ACAna Costas-Carrera
Ana Costas-Carrera
MSMarta Mónica Sánchez-Rodríguez
Marta Mónica Sánchez-Rodríguez
SCSilvia Cañizares
Silvia Cañizares
AOAntonio Ojeda
Antonio Ojeda
IMInés Martín-Villalba
Inés Martín-Villalba
Eduard VietaEduard Vieta
Eduard Vieta
Cognitive manifestations associated with Severe Acute Respiratory Syndrome by Coronavirus 2 (SARS-CoV-2) are yet to be described in the existing literature. The aim of this exploratory study is to analyze the impact of severe SARS-CoV-2 infection on neuropsychological performance 6 months following hospital discharge, and to identify which medical variables predict worse outcome. In this context, we study if cognitive reserve (CR) may play a protective role on cognitive impairment. We enrolled a cohort of 102 severe SARS-CoV-2 survivors who had been admitted to the Intensive Care Unit (ICU) and were contacted 6-months post discharge. A total of 58 agreed to participate in this 6-month follow-up study. Patients with previously known cognitive impairment were excluded. Demographic, clinical and laboratory data were collected. Firstly, to test the magnitude of neurocognitive sequalae two standard deviations below normative group were considered. Secondly, to analyze the main effects of medical variables on cognition and the interaction with cognitive reserve, ANCOVA analyses were performed. 53.4% obtained a score below the cutoff point (<26) in the screening test MOCA. ICU variables including mechanical ventilation, days of sedation or high CRP days were related with cognition. Cognitive Reserve (CR) interacted with delirium (F ​= ​6.8, p ​= ​0.01) and sedation days (F ​= ​9.40, p ​= ​0.003) to predict verbal memory and interacted with high CRP to predict phonemic fluency (F ​= ​6.47, p ​= ​0.01). Finally, no differences in neuropsychological performance were found depending on subjective cognitive impairment (SCI). However, patients with SCI had a higher score in the HAD anxiety subscale (t ​= ​−2.2; p ​< ​0.05). In our cohort, cognitive dysfunction was related with ICU variables such as delirium, mechanical ventilation, and inflammation. CR modulated the impact of these variables on cognition. Cognitive complaints were related with anxiety but not with cognitive performance. Despite some limitations, including the need of replication of the findings with larger samples and control groups, our study suggests that high CR may be protective for severe COVID-19-related cognitive impairment.

24 July 2021 in Trials
Verified
Journal Article
Open access
PDF file
AOAntonio Ojeda
Antonio Ojeda
ACAndrea Calvo
Andrea Calvo
TCTomas Cuñat
Tomas Cuñat
RARicard Mellado Artigas
Ricard Mellado Artigas
OTOscar Comino Trinidad
Oscar Comino Trinidad
CDChristian Dürsteler
Christian Dürsteler
Background: Critically ill patients with COVID-19 are an especially susceptible population to develop post-intensive care syndrome (PICS) due to acute respiratory distress syndrome (ARDS). Patients can suffer acute severe pain and may have long-term mental, cognitive, and functional health deterioration after discharge. However, few controlled trials are evaluating interventions for the prevention and treatment of PICS. The study hypothesis is that a specific care program based on early therapeutic education and psychological intervention improves the quality of life of patients at risk of developing PICS and chronic pain after COVID-19. The primary objective is to determine whether the program is superior to standard-of-care on health-related quality of life at 6 months after hospital discharge. The secondary objectives are to determine whether the intervention is superior to standard-of-care on health-related quality of life, incidence of chronic pain and degree of functional limitation, incidence of anxiety, depression, and post-traumatic stress syndrome at 3 and 6 months after hospital discharge. Methods: The PAINCOVID trial is a unicentric randomized, controlled, patient-blinded superiority trial with two parallel groups. The primary endpoint is the health-related quality of life at 6 months after hospital discharge, and randomization will be performed with a 1:1 allocation ratio. This paper details the methodology and statistical analysis plan of the trial and was submitted before outcome data were available. The estimated sample size is 84 patients, 42 for each arm. Assuming a lost to follow-up rate of 20%, a sample size of 102 patients is necessary (51 for each arm). Discussion: This is the first randomized clinical trial assessing the effectiveness of an early care therapeutic education, and psychological intervention program for the management of PICS and chronic pain after COVID-19. The intervention will serve as proof of the need to implement early care programs at an early stage, having an incalculable impact given the current scenario of the pandemic. Trial registration: This study is being conducted in accordance with the tenets of the Helsinki Declaration and has been approved by the authors’ institutional review board Comité Ético de Investigación Clínica del Hospital Clínic de Barcelona (approval number: HCB/2020/0549) and was registered on May 9, 2020, at clinicaltrials.gov (NCT04394169).

13 January 2024 in Revista Española de Anestesiología y Reanimación
Verified
Journal Article
Closed access
AOA. Ojeda
A. Ojeda
ACA. Calvo
A. Calvo
TCT. Cuñat
T. Cuñat
RMR. Mellado-Artigas
R. Mellado-Artigas
ACA. Costas-Carrera
A. Costas-Carrera
CFC. Ferrando
C. Ferrando

6 August 2025 in Revista Española de Anestesiología y Reanimación
Verified
Journal Article
Closed access
AOA. Ojeda
A. Ojeda
TCT. Cuñat
T. Cuñat
OCO. Comino-Trinidad
O. Comino-Trinidad
JAJ. Aliaga
J. Aliaga
MAM. Arias
M. Arias
ACA. Calvo
A. Calvo

17 January 2024 in Revista Española de Anestesiología y Reanimación (English Edition)
Verified
Journal Article
Closed access
AOA. Ojeda
A. Ojeda
ACA. Calvo
A. Calvo
TCT. Cuñat
T. Cuñat
RMR. Mellado-Artigas
R. Mellado-Artigas
ACA. Costas-Carrera
A. Costas-Carrera
CFC. Ferrando
C. Ferrando